CURIUM
Big PharmaCURIUM is a major pharmaceutical company focused on Oncology, Gastroenterology, Neurology. Key products include DETECTNET.
FDA Novel Drug Designations
(2020)See 1 novel approval →
CURIUM's Key Drugs
CURIUM's core commercial portfolio centers on DETECTNET, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
CURIUM's Recent FDA Approvals
New NDA/BLA approvals for CURIUM over the last two years — novel drugs only, excluding generics and label supplements.
CURIUM's Therapeutic Areas
CURIUM's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 9 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CURIUM's Top Competitors
CURIUM's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, EMD SERONO, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CURIUM Pipeline Snapshot
CURIUM has 4 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DETECTNET leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1971-08-18
- Latest
- 2025-12-10
- Applications
- 21